EndoNaut二维融合成像联合移动C臂用于外周动脉闭塞性疾病腔内治疗
本研究为单中心回顾性非随机对照试验,纳入255例外周动脉疾病患者,比较使用与不使用EndoNaut二维融合成像系统行股腘动脉腔内血运重建的辐射剂量和对比剂用量。结果显示融合成像组对比剂体积和剂量面积乘积均显著低于对照组,复杂病变亚组结果相似。
要点
- 二维融合成像可显著降低外周动脉腔内治疗的对比剂用量和辐射剂量。
- 复杂病变(TASC C/D)亚组中融合成像的获益与总体结果一致。
- 融合成像组对比剂和辐射剂量降低幅度均超过30%,且无需过多培训。
核心结论
- 应用EndoNaut二维融合成像技术行外周动脉疾病腔内治疗可显著降低对比剂体积和辐射剂量。
研究设计与样本
- 单中心、回顾性、非随机对照试验,纳入255例股腘动脉及/或胫动脉段外周动脉疾病患者,均接受腔内血运重建。
- 患者分为使用EndoNaut二维融合成像系统组(n=124)和未使用组(n=131),均在非杂交手术室使用同一Cios Alpha移动C臂。
主要发现
- 融合成像组对比剂注射体积为34.7 ± 13.8 mL,对照组为51.3 ± 26.7 mL(P < .001)。
- 融合成像组剂量面积乘积为8.9 ± 9.9 Gy/cm2,对照组为13.5 ± 14.0 Gy/cm2(P = .003)。
- 复杂病变(TASC C/D)亚组分析显示相似结果。
- 按手术日期将融合成像组分为三个亚组,未观察到学习曲线对手术参数的影响。
临床怎么用
- 在非杂交手术室使用移动C臂行外周动脉腔内血运重建时,可考虑应用二维融合成像技术以减少对比剂用量和辐射暴露。
- 该技术无需过多培训即可实施,可能有助于提升手术安全性。
局限性
- 本研究为单中心回顾性非随机对照试验,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular treatment has become the first-line strategy for peripheral arterial disease (PAD). Given the number of procedures required, any technology associated with a reduction in radiation exposure and contrast volume is highly relevant. In the present study, we evaluated whether two-dimensional (2D) fusion imaging could reduce the radiation exposure and contrast volume during endovascular treatment of occlusive PAD. METHODS: Our consecutive, retrospective, single-center, nonrandomized comparative trial included patients with PAD at the femoral, popliteal, and/or tibial level, at any clinical stage, if they were candidates for endovascular revascularization. Patients were treated with or without the EndoNaut 2D fusion imaging system (Therenva, Rennes, France) in a nonhybrid room with the same Cios Alpha mobile C-arm (Siemens, Munich, Germany). The indirect dose-area product and contrast medium volume were recorded. RESULTS: Between March 2018 and April 2020, 255 patients underwent endovascular femoropopliteal revascularization with (n = 124) or without (n = 131) 2D fusion imaging. The volume of injected contrast medium (34.7 ± 13.8 mL vs 51.3 ± 26.7 mL; P < .001) and dose-area product (8.9 ± 9.9 Gy/cm2 vs 13.5 ± 14.0 Gy/cm2; P = .003) were significantly lower for the 2D fusion imaging group than for the control group. A subgroup analysis of complex (TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease C/D) lesions showed similar results. Stratification of the fusion imaging group into three subgroups, according to the procedure dates, showed no effect of a potential learning curve on the operative parameters. CONCLUSIONS: The results from the present study showed a significant reduction in the contrast volume and radiation dose for endovascular treatment of PAD when applying 2D fusion imaging technology. Overall, a reduction of >30% was observed for both operative parameters, without excessive training requirements, highlighting the potential benefits of using 2D fusion imaging when performing endovascular revascularization for PAD.
引用
- Caradu C, Stenson K, Houmaïda H, et al. EndoNaut two-dimensional fusion imaging with a mobile C-arm for endovascular treatment of occlusive peripheral arterial disease. J Vasc Surg. 2021. PMID: 34509588. doi:10.1016/j.jvs.2021.08.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。